Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

0.7600 +0.0200 (+2.70%)
Streaming Delayed Price Updated: 11:27 AM EDT, Mar 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
These stocks have an unusual volume in today's session ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
Discover the top movers in Friday's pre-market session. ↗
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine’s Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Friday? ↗
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.